429 related articles for article (PubMed ID: 17720276)
1. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials.
Rajeswaran A; Trojan A; Burnand B; Giannelli M
Lung Cancer; 2008 Jan; 59(1):1-11. PubMed ID: 17720276
[TBL] [Abstract][Full Text] [Related]
2. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer.
Jiang J; Liang X; Zhou X; Huang R; Chu Z
Lung Cancer; 2007 Sep; 57(3):348-58. PubMed ID: 17485133
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
Vasconcellos VF; Marta GN; da Silva EM; Gois AF; de Castria TB; Riera R
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD009256. PubMed ID: 31930743
[TBL] [Abstract][Full Text] [Related]
4. Best first-line therapy for people with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status.
Gijtenbeek RG; de Jong K; Venmans BJ; van Vollenhoven FH; Ten Brinke A; Van der Wekken AJ; van Geffen WH
Cochrane Database Syst Rev; 2023 Jul; 7(7):CD013382. PubMed ID: 37419867
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
de Castria TB; da Silva EM; Gois AF; Riera R
Cochrane Database Syst Rev; 2013 Aug; (8):CD009256. PubMed ID: 23949842
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis.
Griesinger F; Korol EE; Kayaniyil S; Varol N; Ebner T; Goring SM
Lung Cancer; 2019 Sep; 135():196-204. PubMed ID: 31446995
[TBL] [Abstract][Full Text] [Related]
7. [A meta-analysis of the curative effects of carboplatin-based and cisplatin-based chemotherapeutic regimens on advance non-small cell lung cancer].
Jiang JW; Liang XH; Zhou XL; Huang RF
Zhonghua Yi Xue Za Zhi; 2006 Oct; 86(37):2615-20. PubMed ID: 17198587
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy for advanced non-small cell lung cancer in the elderly population.
Santos FN; de Castria TB; Cruz MR; Riera R
Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD010463. PubMed ID: 26482542
[TBL] [Abstract][Full Text] [Related]
9. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature.
D'Addario G; Pintilie M; Leighl NB; Feld R; Cerny T; Shepherd FA
J Clin Oncol; 2005 May; 23(13):2926-36. PubMed ID: 15728229
[TBL] [Abstract][Full Text] [Related]
10. Platinum-containing regimens for metastatic breast cancer.
Egger SJ; Willson ML; Morgan J; Walker HS; Carrick S; Ghersi D; Wilcken N
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD003374. PubMed ID: 28643430
[TBL] [Abstract][Full Text] [Related]
11. Comparing single-agent with doublet chemotherapy in first-line treatment of advanced non-small cell lung cancer with performance status 2: a meta-analysis.
Luo L; Hu Q; Jiang JX; Yang X; Dinglin XX; Lin X; Yao HR
Asia Pac J Clin Oncol; 2015 Sep; 11(3):253-61. PubMed ID: 25866140
[TBL] [Abstract][Full Text] [Related]
12. Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data.
Rossi A; Chiodini P; Sun JM; O'Brien ME; von Plessen C; Barata F; Park K; Popat S; Bergman B; Parente B; Gallo C; Gridelli C; Perrone F; Di Maio M
Lancet Oncol; 2014 Oct; 15(11):1254-62. PubMed ID: 25232001
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin-Based Doublets Versus Cisplatin or Carboplatin-Based Doublets in the First-Line Treatment of Advanced Nonsmall Cell Lung Cancer.
Yu J; Xiao J; Yang Y; Cao B
Medicine (Baltimore); 2015 Jul; 94(27):e1072. PubMed ID: 26166081
[TBL] [Abstract][Full Text] [Related]
14. Doublet versus single cytotoxic agent as first-line treatment for elderly patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Qi WX; Tang LN; He AN; Shen Z; Lin F; Yao Y
Lung; 2012 Oct; 190(5):477-85. PubMed ID: 22711060
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis comparing doublet and single cytotoxic agent therapy as first-line treatment in elderly patients with advanced nonsmall-cell lung cancer.
Wang S; Wang Q; Tian J; Zhou Z; Jiao L; Fu Y; Chen S; Zhang J; Xu L
J Int Med Res; 2015 Dec; 43(6):727-37. PubMed ID: 26438014
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of the unresectable non small cell lung carcinoma].
Spásová I
Cas Lek Cesk; 2005; 144(9):602-12; discussion 612-3. PubMed ID: 16193938
[TBL] [Abstract][Full Text] [Related]
17. A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): paclitaxel plus carboplatin versus vinorelbine plus cisplatin.
Chang WJ; Sun JM; Lee JY; Ahn JS; Ahn MJ; Park K
Lung Cancer; 2014 Apr; 84(1):51-5. PubMed ID: 24521819
[TBL] [Abstract][Full Text] [Related]
18. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin vs. carboplatin-based chemoradiotherapy in patients >65 years of age with stage III non-small cell lung cancer.
Ezer N; Smith CB; Galsky MD; Mhango G; Gu F; Gomez J; Strauss GM; Wisnivesky J
Radiother Oncol; 2014 Aug; 112(2):272-8. PubMed ID: 25150635
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer.
Hotta K; Matsuo K; Ueoka H; Kiura K; Tabata M; Tanimoto M
J Clin Oncol; 2004 Oct; 22(19):3852-9. PubMed ID: 15326195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]